DGAP-News: STRATEC Biomedical AG / Key word(s): AGM/EGM STRATEC Annual General Meeting resolves dividend payment amounting to EUR 0.70 per share 22.05.2015 / 20:27 --------------------------------------------------------------------- STRATEC Annual General Meeting resolves dividend payment amounting to EUR 0.70 per share Birkenfeld, May 22, 2015 The Shareholders of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) approved all of the agenda items put to the vote at today's Annual General Meeting in Pforzheim with the necessary majorities in each case. The shareholders present represented 72.85% of the company's share capital. As proposed, STRATEC will distribute a dividend of EUR 0.70 per share to its shareholders for the 2014 financial year (previous year: EUR 0.60). The distribution total amounts to EUR 8.2 million and will be paid to shareholders via their depository banks on May 26, 2015. The dividend has thus been increased for the eleventh year in succession since the initiation of dividend payments in 2004. Furthermore, Ebner Stolz GmbH & Co. KG, Stuttgart, was elected as auditor for the 2015 financial year. It was also decided to convert the company's shares from bearer to registered shares. This conversion is due to be implemented in the second half of 2015. The Annual General Meeting also once again approved the creation of authorized and conditional capitals, an authorization to acquire and sell own shares, and various amendments to the Articles of Association. Further information about our Annual General Meeting can be found on the company's website at www.stratec.com/agm, where details of voting results have also been published. About STRATEC STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange. Further information can be obtained from: STRATEC Biomedical AG André Loy, Investor Relations Gewerbestr. 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 ir@stratec.com www.stratec.com --------------------------------------------------------------------- 22.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec.com Internet: www.stratec.com ISIN: DE0007289001 WKN: 728900 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 361391 22.05.2015
DGAP-News: STRATEC Annual General Meeting resolves dividend payment amounting to EUR 0.70 per share
| Source: EQS Group AG